NCT04550325View on ClinicalTrials.gov

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

November 26, 2020

Study Completion Date

November 26, 2020

Conditions

Covid19Pneumonia, Viral

Interventions

BIOLOGICAL

Kamada Anti-SARS-CoV-2

Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods

Trial Locations (4)

52621

Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan

91120

Hadassah Medical Center, Jerusalem

5822012

Wolfson Medical Center, Holon

7661041

Kaplan Medical Center, Rehovot

All Listed Sponsors

lead

Kamada, Ltd.

INDUSTRY

NCT04550325 - Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 | Biotech Hunter | Biotech Hunter